BioMarin Pharmaceutical Inc.

95.03-1.91-1.97%Vol 711.92K1Y Perf 29.08%
Aug 16th, 2022 16:00 DELAYED
BID92.77 ASK98.00
Open97.00 Previous Close96.94
Pre-Market- After-Market95.06
 - -  0.03 0.03%
Target Price
111.23 
Analyst Rating
Strong Buy 1.32
Potential %
17.05 
Finscreener Ranking
★★★★     53.94
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★+     50.00
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★     57.26
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
89.90 
Earnings Rating
Sell
Market Cap17.63B 
Earnings Date
3rd Aug 2022
Alpha-0.00 Standard Deviation0.08
Beta0.33 

Today's Price Range

94.7797.00

52W Range

70.7397.76

5 Year PE Ratio Range

-487.5020.80

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-1.01%
1 Month
9.13%
3 Months
20.11%
6 Months
5.24%
1 Year
29.08%
3 Years
24.22%
5 Years
17.35%
10 Years
150.41%

TickerPriceChg.Chg.%
BMRN95.03-1.9100-1.97
AAPL173.03-0.1600-0.09
GOOG122.51-0.3700-0.30
MSFT292.71-0.7600-0.26
XOM91.46-0.8600-0.93
WFC46.060.31000.68
JNJ167.571.48000.89
FB196.640.99000.51
GE81.071.26001.58
JPM123.631.17000.96
 
ProfitabilityValueIndustryS&P 500US Markets
75.80
3.70
9.20
-8.30
2.83
RevenueValueIndustryS&P 500US Markets
1.91B
10.31
5.88
9.42
Earnings HistoryEstimateReportedSurprise %
Q02 20220.200.3365.00
Q01 20220.150.31106.67
Q04 2021-0.22-0.214.55
Q03 2021-0.12-0.0375.00
Q02 20210.050.23360.00
Q01 20210.070.29314.29
Q04 2020-0.06-0.0516.67
Q03 2020-0.010.293.00K
Earnings Per EndEstimateRevision %Trend
6/2022 QR0.20-33.33Negative
9/2022 QR0.15-25.00Negative
12/2022 FY0.956.74Positive
12/2023 FY2.58-3.37Negative
Next Report Date-
Estimated EPS Next Report0.20
Estimates Count8
EPS Growth Next 5 Years %50.40
Volume Overview
Volume711.92K
Shares Outstanding185.47K
Shares Float184.17M
Trades Count12.19K
Dollar Volume68.04M
Avg. Volume1.10M
Avg. Weekly Volume1.12M
Avg. Monthly Volume1.06M
Avg. Quarterly Volume1.13M

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) stock closed at 95.03 per share at the end of the most recent trading day (a -1.97% change compared to the prior day closing price) with a volume of 711.92K shares and market capitalization of 17.63B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3059 people. BioMarin Pharmaceutical Inc. CEO is Jean-Jacques Bienaime.

The one-year performance of BioMarin Pharmaceutical Inc. stock is 29.08%, while year-to-date (YTD) performance is 7.56%. BMRN stock has a five-year performance of 17.35%. Its 52-week range is between 70.73 and 97.76, which gives BMRN stock a 52-week price range ratio of 89.90%

BioMarin Pharmaceutical Inc. currently has a PE ratio of 365.70, a price-to-book (PB) ratio of 3.91, a price-to-sale (PS) ratio of 9.41, a price to cashflow ratio of 148.40, a PEG ratio of 2.32, a ROA of 0.90%, a ROC of 1.11% and a ROE of 1.24%. The company’s profit margin is 2.83%, its EBITDA margin is 9.20%, and its revenue ttm is $1.91 Billion , which makes it $10.31 revenue per share.

Of the last four earnings reports from BioMarin Pharmaceutical Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.20 for the next earnings report. BioMarin Pharmaceutical Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for BioMarin Pharmaceutical Inc. is Strong Buy (1.32), with a target price of $111.23, which is +17.05% compared to the current price. The earnings rating for BioMarin Pharmaceutical Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioMarin Pharmaceutical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioMarin Pharmaceutical Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 14.57, ATR14 : 2.45, CCI20 : 98.82, Chaikin Money Flow : 0.18, MACD : 3.23, Money Flow Index : 68.74, ROC : 11.32, RSI : 72.42, STOCH (14,3) : 93.73, STOCH RSI : 0.88, UO : 62.34, Williams %R : -6.27), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioMarin Pharmaceutical Inc. in the last 12-months were: Brian Mueller (Sold 0 shares of value $-237 335 ), Brian Mueller (Sold 10 837 shares of value $987 412 ), Charles Greg Guyer (Sold 6 205 shares of value $599 155 ), Dennis J. Slamon (Sold 6 296 shares of value $493 178 ), Elaine J. Heron (Sold 0 shares of value $-318 410 ), G. Eric Davis (Sold 0 shares of value $-4 572 497 ), G. Eric Davis (Sold 101 566 shares of value $9 044 118 ), Jean-Jacques Bienaime (Sold 0 shares of value $-4 345 360 ), Jean-Jacques Bienaime (Sold 116 500 shares of value $9 483 282 ), Jeffrey R. Ajer (Sold 16 428 shares of value $1 309 691 ), Richard A. Meier (Sold 0 shares of value $-318 410 ), Richard A. Meier (Sold 3 878 shares of value $318 345 ), V. Bryan Lawlis (Sold 0 shares of value $-318 410 ), V. Bryan Lawlis (Sold 8 500 shares of value $727 898 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (78.57 %)
10 (71.43 %)
10 (76.92 %)
Moderate Buy
1 (7.14 %)
1 (7.14 %)
1 (7.69 %)
Hold
2 (14.29 %)
3 (21.43 %)
2 (15.38 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.32
Strong Buy
1.46
Strong Buy
1.35

BioMarin Pharmaceutical Inc.

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.

CEO: Jean-Jacques Bienaime

Telephone: +1 415 506-6700

Address: 770 Lindaro Street, San Rafael 94901, CA, US

Number of employees: 3 059

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

70%30%

Bearish Bullish

66%34%

TipRanks News for BMRN

Fri, 12 Aug 2022 09:04 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), BioMarin Pharmaceutical (BMRN) and Enovis (ENOV)

- TipRanks. All rights reserved.

Thu, 04 Aug 2022 16:43 GMT Morgan Stanley Believes BioMarin Pharmaceutical (BMRN) Still Has Room to Grow

- TipRanks. All rights reserved.

Mon, 25 Jul 2022 09:22 GMT BioMarin Pharmaceutical (BMRN) Receives a Buy from SVB Securities

- TipRanks. All rights reserved.

Fri, 22 Jul 2022 03:45 GMT Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Illumina (ILMN) and Ionis Pharmaceuticals (IONS)

- TipRanks. All rights reserved.

Wed, 13 Jul 2022 18:55 GMT BioMarin Pharmaceutical (BMRN) Gets a Hold Rating from Wedbush

- TipRanks. All rights reserved.

Mon, 13 Jun 2022 11:15 GMT Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Medicinova (MNOV)

- TipRanks. All rights reserved.

Tue, 31 May 2022 17:25 GMT BioMarin Pharmaceutical (BMRN) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Fri, 20 May 2022 03:55 GMT Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Thermo Fisher (TMO) and Atreca (BCEL)

- TipRanks. All rights reserved.

Sat, 30 Apr 2022 01:46 GMT BioMarin Pharmaceutical (BMRN) Receives a Hold from RBC Capital

- TipRanks. All rights reserved.

Thu, 28 Apr 2022 10:45 GMT Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Sanofi (OtherSNYNF)

- TipRanks. All rights reserved.

Sat, 26 Feb 2022 15:55 GMT BioMarin Pharmaceutical (BMRN) Gets a Buy Rating from Robert W. Baird

- TipRanks. All rights reserved.

Mon, 10 Jan 2022 14:05 GMT Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Icosavax (ICVX)

- TipRanks. All rights reserved.

Mon, 10 Jan 2022 13:55 GMT Analysts Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Autolus Therapeutics (AUTL)

- TipRanks. All rights reserved.

Thu, 06 Jan 2022 14:05 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (BMRN), Illumina (ILMN) and Catalent (CTLT)

- TipRanks. All rights reserved.

News

Stocktwits